| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC1817 | D-lana-14 | Novel potent anti-MRSA agent, disrupting biofilms with no resistance development, sensitizing rifampicin and tetracycline against multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa |
|
| DCC1818 | Dlc27-14 | Specific protein disorder catalyzer of HIV-1 Nef |
|
| DCC1819 | Dl-threo-dihydrosphingosine | Competitive inhibitor of both SPHK1 and SPHK2 |
|
| DCC1820 | D-luciferin Phosphate Sodium Salt | Ultrasensitive bioluminogenic enzyme substrate |
|
| DCC1821 | D-lys(z)-pro-arg-pna | Chromogenic peptide substrate, being highly sensitive for the measurement of activated Protein C. |
|
| DCC1822 | Dma-cpptl | Prodrug of CPPTL, inducing apoptosis in a dose-dependent manner via the ROS/JNK pathway in acute myeloid leukemia |
|
| DCC1823 | Dmako-20 | Novel multi-target anticancer prodrug activated by the tumor specific CYP1B1 enzyme, potently inhibiting HCT-15, HCT-116 and K562 cells growth, showing moderate anti-proliferative activity towards MDA-MB-231, HepG2, PANC, Bel7402 and MGC803 cancer cells, |
|
| DCC1824 | Dmako-5 | Novel antineoplastic agent, exhibiting remarkable anticancer activity as well as excellent cellular selectivity |
|
| DCC1825 | D-mannuronic Acid [6906-37-2] | Novel blocker of the TLR2 and TLR4 downstream signaling pathway, effectively inhibiting mRNA expression of MyD88 and p65, major subunit of nuclear factor-kappaB |
|
| DCC1826 | Dmb213 | Novel non-nucleoside inhibitor of Zika viral RNA-dependent RNA polymerase (RdRp) enzymes |
|
| DCC1827 | Dmcl1-2 | Novel potent and selective PROTAC degrader of myeloid cell leukemia 1 (MCL1) |
|
| DCC1828 | Dmnpe-caged Luciferin | Novel cell permeable caged Luciferin |
|
| DCC1829 | Dmocptl | Novel inducer of ferroptosis and apoptosis through ubiquitination of GPX4 in triple negative breast cancer cells |
|
| DCC1830 | Dmt-dalda | Potent and highly selective µ opioid agonist |
|
| DCC1831 | Dmxb-a | Novel,orally active and selective alpha-7 nicotinic acetylcholine (nACh) receptor |
|
| DCC1832 | Dna Primase Inhibitor-1 | Novel DNA primase inhibitor |
|
| DCC1833 | Dna Primase Inhibitor-13 | Novel DNA primase inhibitor |
|
| DCC1834 | Dnac-1 | Novel potentiator of β-lactam activity against Gram positive and Gram negative pathogens |
|
| DCC1835 | Dndi-0690 | Novel antitubercular and antiparasitic agent, possessing excellent in vitro activity against both L. donovani and Leishmania infantum as well as displaying a better safety profile |
|
| DCC1836 | Do-601 | Analeptic agent, stimulating central nervous system; Anti-barbiturate-overdose |
|
| DCC1837 | Dolastatin 10 Featured | Highly potent cytotoxic microtubule inhibitor |
|
| DCC1838 | Doot-2d | Selective MAO-B inhibitor |
|
| DCC1839 | Dora 42 | Dual orexin receptor antagonist (OX1R and OX2R antagonist or DORA) |
|
| DCC1840 | Doramectin | Anthelmintic, for the treatment of parasites such as gastrointestinal roundworms, lungworms, eyeworms, grubs, sucking lice and mange mites in cattle |
|
| DCC1841 | Dothiepin Hydrochloride | Tricyclic antidepressant (TCA), acting as a serotonin–norepinephrine reuptake inhibitor (SNRI) and also having other activities including antihistamine, antiadrenergic, antiserotonergic, anticholinergic, and sodium channel-blocking effects |
|
| DCC1842 | Dov51892 | Agonist of GABAA receptors α15 subunits |
|
| DCC1843 | Dp-326 | Novel antibacterial with activity against the Gram-negative bacteria associated with nosocomial infections |
|
| DCC1844 | Dpa-154 | Novel effective and selective inhibitor of E. coli topoisomerase I |
|
| DCC1845 | Dpb163-ae | Novel 2-aminoethyl diphenylborinate (2-APB) analogue, inducing a profound activation of SOCE in DT40 cells, albeit at low concentrations (10 nM), blocking the melatonin-induced [Ca ] cyt increase and SOCE in P. falciparum. |
|
| DCC1846 | Dpbx-l-dopa | Novel boron-containing dopa-derivative, acting as a bladder relaxant through non-catecholamine receptors |
|
